Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Medicines on shelf - Prasanth - stock.adobe.com.jpg
Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential

April 24th 2025

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial

April 10th 2025

Psoriasis oral treatment | Image credit: Pawel - stock.adobe.com
Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors

April 7th 2025

Psoriasis treatment concept | Sviatlana - stock.adobe.com
Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

April 1st 2025

Bimekizumab | Image credit: luchschenF - stock.adobe.com
Bimekizumab Reduces Inflammation, Cardiovascular Risk

March 21st 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
April 25th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
April 25th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Utilizing Lower Volume Agents for Plaque Psoriasis and MetS
January 18th 2022

Utilizing Lower Volume Agents for Plaque Psoriasis and MetS

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.
Person comforting other individual.
January 15th 2022

Heightened Depressive, Anxiety Burden Found in Patients With Comorbid Psoriasis and PsA

Matthew Gavidia
Patients with comorbid psoriasis and psoriatic arthritis exhibited significantly higher rates of depression and anxiety vs those with psoriasis alone, whereas lifetime suicidality prevalence was not different between the 2 groups but still heightened compared with the general population.
2 physicians working.
January 12th 2022

Adjuvant Ultraviolet-Based Therapy More Effective vs Monotherapy in Psoriasis

Matthew Gavidia
Patients with psoriasis exhibited superior efficacy outcomes when treated with ultraviolet (UV)-based phototherapy plus other adjuvant therapies vs UV monotherapy, with similar safety profiles shown for both approaches.
Utilizing Real-World Evidence for Cost/Value Analyses
January 11th 2022

Utilizing Real-World Evidence for Cost/Value Analyses

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.
Population Health and MetS
January 11th 2022

Population Health and MetS

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.
Person scratching neck.
January 7th 2022

Comorbidities in Patients With Psoriasis Linked With More Severe Skin Lesions, Adverse Treatment Outcomes

Matthew Gavidia
Patients with psoriasis who had comorbidities were associated with worse health-related quality of life and impaired treatment outcomes with conventional therapy, whereas biologic treatments maintained high efficacy despite presence of co-occuring conditions.
Elderly hands.
January 4th 2022

Spesolimab Linked With Higher Incidence of Lesion Clearance, Adverse Reactions in Patients With Pustular Psoriasis

Matthew Gavidia
Treatment with the interleukin-36 inhibitor spesolimab was associated with improved lesion clearance vs placebo after one week, but also a greater incidence of infection and systemic drug reactions.
Identifying Responder and Non-Responders Early in the Psoriasis Treatment Plan
January 4th 2022

Identifying Responder and Non-Responders Early in the Psoriasis Treatment Plan

Dr Lebwohl explains how he can recognize who will respond early to psoriasis treatments and who won’t respond at all.
Switching Among Biologics for Patients With Psoriasis
January 4th 2022

Switching Among Biologics for Patients With Psoriasis

Bhavesh Shah, PharmD, elaborates on switching biologics in psoriasis treatment.
Designing Appropriate Treatment Regimens for Patients With Psoriasis and MetS
December 28th 2021

Designing Appropriate Treatment Regimens for Patients With Psoriasis and MetS

Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.
Doctor looking at a EHR.
December 27th 2021

Psoriasis Severity, Treatment Outcomes Differ Across US Regions

Matthew Gavidia
Psoriasis severity and treatment outcomes were found to differ across US geographic regions, in which the East South Central and West South Central regions were associated with the greatest frequencies of very severe disease burden and decreased likelihood of achieving targeted response within 6 months of initiating biologic therapy.
Hospitalized child.
December 22nd 2021

Tobacco Exposure May Increase Psoriasis Risk in Children

Matthew Gavidia
Childhood psoriasis was found to be significantly associated with environmental tobacco smoke exposure, whereas intrauterine smoking exposure was not associated with an increased risk in pediatric populations.
Extrapolating Clinical Data for Decision-Making
December 21st 2021

Extrapolating Clinical Data for Decision-Making

Mark Lebwohl, MD, details how he extrapolates clinical data in his decision-making when trying to treat patients with psoriasis.
Payer Considerations When Treating Psoriasis With Different Therapeutics
December 21st 2021

Payer Considerations When Treating Psoriasis With Different Therapeutics

Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.
Psoriasis top 5 articles
December 20th 2021

Top 5 Most-Read Psoriasis Articles of 2021

Matthew Gavidia
The top 5 most-read psoriasis articles of 2021 on AJMC.com covered risk factors involved in the pathogenesis and treatment of psoriatic disease and cost considerations for treatment.
Spotlighting a patient.
December 18th 2021

Study Finds No Standardized Treatment, Continued Health Care Utilization in Pustular Psoriasis

Matthew Gavidia
A case series of patients with pustular psoriasis indicated a lack of standardized treatment and continued health care utilization, in which men were at greater risk of an emergency department or hospital encounter.
Doctor and patient.
December 15th 2021

Comorbid Psoriasis, NAFLD Linked With Significantly Impaired Kidney Function

Matthew Gavidia
Patients with comorbid nonalcoholic fatty liver disease (NAFLD) and chronic plaque psoriasis were shown to have significantly lower estimated glomerular filtration rate levels and greater prevalence of more advanced chronic kidney disease.
Effectiveness of Treatment Options in Patients With Psoriasis and MetS
December 15th 2021

Effectiveness of Treatment Options in Patients With Psoriasis and MetS

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.
Increased Risk of Metabolic Syndrome in Patients With Psoriasis
December 15th 2021

Increased Risk of Metabolic Syndrome in Patients With Psoriasis

Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.
Patient Adherence With Psoriasis Treatments
December 13th 2021

Patient Adherence With Psoriasis Treatments

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.
Disease Burden for Patients With Plaque Psoriasis
December 13th 2021

Disease Burden for Patients With Plaque Psoriasis

Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.
Physician with patient.
December 9th 2021

Nail Involvement May Reduce Efficacy of Ustekinumab For Psoriasis

Matthew Gavidia
Nail involvement was shown to reduce the effectiveness of ustekinumab in the treatment of moderate to severe psoriasis, whereas secukinumab exhibited overall higher efficacy than ustekinumab and similar response rates regardless of nail involvement.
Person clasping hand.
December 6th 2021

Patients With Psoriatic Disease May Have Greater Risk of VTE, PVD

Matthew Gavidia
Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.
Person touching neck.
December 2nd 2021

Brodalumab Improves Skin Clearance, QOL vs Ustekinumab in Comorbid Psoriasis, PsA

Matthew Gavidia
Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).
Physician and patient.
November 29th 2021

TNF Inhibitors Show Real-world Efficacy on QOL of Patients With Nail Psoriasis, PsA

Matthew Gavidia
Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.
Magnifying risk in one person of a group.
November 26th 2021

Assessing Risk Factors for PsA Development in Patients With Psoriasis

Matthew Gavidia
Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.
Health care cost.
November 20th 2021

Greater Work Impairment, Comorbidity Burden Linked With Concomitant Psoriasis, PsA

Matthew Gavidia
Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.
Elderly person's hands.
November 17th 2021

Guselkumab Linked With Long-term Improvement of Joint Manifestations, Disease Activity in PsA

Matthew Gavidia
Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.
Pill bottle.
November 12th 2021

Prior Biologic Use, Body Weight May Impact Guselkumab Efficacy in Psoriasis

Matthew Gavidia
Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.
Psoriasis on hand.
November 9th 2021

Real-world Findings Show Apremilast Effective Long Term in Plaque Psoriasis

Matthew Gavidia
Findings of a real-world, single-center study indicated that apremilast was effective and safe long-term in the treatment of moderate-to-severe plaque psoriasis.
<1
...
456789101112
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo